Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
4 Top-Ranked Stocks Poised to Beat on Q4 Earnings Next Week
by Nalak Das
For fourth-quarter 2019, earnings trends are improving as companies are coming up with their reports.
Alexion Pharmaceuticals (ALXN) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
New Strong Buy Stocks for January 23rd
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
3 Reasons Why Alexion (ALXN) Is a Great Growth Stock
by Zacks Equity Research
Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.
ALXN vs. QGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ALXN vs. QGEN: Which Stock Is the Better Value Option?
5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Top Ranked Growth Stocks to Buy for January 22nd
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 22nd.
Mersana Therapeutics (MRSN) Looks Good: Stock Adds 5.8% in Session
by Zacks Equity Research
Mersana Therapeutics (MRSN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
New Strong Buy Stocks for January 20th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Top Ranked Growth Stocks to Buy for January 20th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 20th
Alexion to Start Pivotal Study on Ultomiris for ALS in Q1
by Zacks Equity Research
Alexion (ALXN) plans to initiate a phase III study on Ultomiris (ravulizumab) to treat amyotrophic lateral sclerosis.
Momenta (MNTA) Provides Pipeline Updates, Stock Rallies
by Zacks Equity Research
Shares of Momenta (MNTA) rise 23.7% on pipeline updates.
Alexion Pharmaceuticals (ALXN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $112.79 in the latest trading session, marking a -0.99% move from the prior day.
Ultragenyx Provides Preliminary Crysvita 2019 Revenues
by Zacks Equity Research
Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.
Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari
by Zacks Equity Research
Alnylam (ALNY) announces preliminary results for the fourth quarter and 2019 and provides other updates.
Ultragenyx's Gene Therapy Positive in Genetic Disorder Study
by Zacks Equity Research
Shares of Ultragenyx (RARE) rise 23.4% after releasing positive top-line data from the phase I/II study of its gene therapy candidate DTX301 for the treatment of OTC deficiency.
New Strong Buy Stocks for January 13th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
Top Ranked Growth Stocks to Buy for January 13th
by Zacks Equity Research
Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 13th.
Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
by Zacks Equity Research
Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.
Has Alexion Pharmaceuticals (ALXN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ALXN) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: H&R Block, Berry Global Group, Emergent BioSolutions, Pilgrim's Pride and Alexion Pharmaceuticals
Incyte's Application for Pemigatinib Gets EMA's Validation
by Zacks Equity Research
The EMA endorses Incyte's (INCY) MAA for pemigatinib to treat locally advanced/metastatic cholangiocarcinoma with a FGFR2 fusion that is relapsed or refractory post minimum one line of systemic therapy.
Amarin Posts '19 Preliminary Results, Gives 2020 Expense View
by Zacks Equity Research
Amarin's (AMRN) Vascepa sales witness strong growth. The trend is anticipated to continue in 2020. However, the operating expense guidance for 2020 was higher than expected, which probably pulled the stock down.